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No Evidence of Association Between Prothrombotic Gene
Polymorphisms and the Development of Acute Myocardial
Infarction at a Young Age
Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group*
Background—We investigated the association between 9 polymorphisms of genes encoding hemostasis factors and
myocardial infarction in a large sample of young patients chosen because they have less coronary atherosclerosis than
older patients, and thus their disease is more likely to be related to a genetic predisposition to a prothrombotic state.
Methods and Results—This nationwide case-control study involved 1210 patients who had survived a first myocardial
infarction at an age of 45 years who underwent coronary arteriography in 125 coronary care units and 1210 healthy
subjects matched for age, sex, and geographical origin. None of the 9 polymorphisms of genes encoding proteins
involved in coagulation (G-455A -fibrinogen: OR, 1.0; CI, 0.8 to 1.2; G1691A factor V: OR, 1.1; CI, 0.6 to 2.1;
G20210A factor II: OR, 1.0; CI, 0.5 to 1.9; and G10976A factor VII: OR, 1.0; CI, 0.8 to 1.3), platelet function (C807T
glycoprotein Ia: OR, 1.1; CI, 0.9 to 1.3; and C1565T glycoprotein IIIa: OR, 0.9; CI, 0.8 to 1.2), fibrinolysis (G185T
factor XIII: OR, 1.2; CI, 0.9 to 1.6; and 4G/5G plasminogen activator inhibitor type 1: OR, 0.9; CI, 0.7 to 1.2), or
homocysteine metabolism (C677T methylenetetrahydrofolate reductase: OR, 0.9; CI, 0.8 to 1.1) were associated with
an increased or decreased risk of myocardial infarction.
Conclusions—This study provides no evidence supporting an association between 9 polymorphisms of genes encoding
proteins involved in hemostasis and the occurrence of premature myocardial infarction or protection against it.
(Circulation. 2003;107:1117-1122.)
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Although the role of environmental factors in the devel-opment of acute myocardial infarction has been clearly
established, the role of genetic factors (particularly those
related to thrombogenesis) is still undefined. A number of
relatively small case-control studies, usually of middle-aged
and elderly patients, have assessed the association between
various polymorphisms of genes encoding factors involved in
the hemostatic system, each of which was usually studied
separately, and susceptibility to or protection against myocar-
dial infarction.1,2 However, the results were conflicting or of
borderline statistical significance, not only because of the
inadequate sample sizes of the majority of these studies but
also because of the confounding effect of atherosclerosis,
which is highly prevalent in middle-aged and elderly patients.
When acute myocardial infarction occurs in the young, there
is usually less coronary atherosclerosis, and the prevalence of
normal or near-normal coronary angiograms is high, partic-
ularly in women.3 It is therefore biologically plausible that
changes in hemostasis factors leading to prothrombotic phe-
notypes of hypercoagulability, heightened platelet function,
hypofibrinolysis, and hyperhomocystinemia (as well as their
genetic determinants) play a relevant role in younger patients
with myocardial infarction. In this matched case-control
study, we evaluated the association between 9 of the most
frequently investigated polymorphisms of genes encoding
hemostasis factors and the occurrence of myocardial infarc-
tion. The study is distinguished by 2 main features: its sample
size and the choice of case patients who had developed
myocardial infarction at a young age.
Methods
Case and Control Patients
This nationwide case-control study involved 125 Italian coronary
care units. The 1210 case patients (cases) were patients hospitalized
for a first myocardial infarction before the age of 45 years who
underwent coronary arteriography at the time of hospitalization. The
1210 control patients (controls) were healthy subjects unrelated to
the cases but individually matched with them in terms of age, sex,
and geographical origin who were enrolled from among the staff of
the same participating hospitals; they had no history of thromboem-
bolic disease. The cases and controls were enrolled between January
1998 and January 2001.
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All of the participants were given a standardized questionnaire
concerning cardiovascular risk factors, medical diagnosis, lifestyle,
and medication. The collected data included age, sex, and traditional
risk factors such as a family history of ischemic heart disease,
smoking, high serum cholesterol levels, diabetes, hypertension, and
cocaine use. Alcohol intake and the levels and pattern of physical
exercise were also recorded. The data relating to the cases were
collected at the time of their first myocardial infarction and those
relating to the controls at the time of the hospital evaluation for study
enrollment. All of the study participants agreed to give blood
samples for DNA analysis and cholesterol measurements. The
Institutional Review Boards of the participating hospitals approved
the study, and the cases and controls gave their written informed
consent.
Definitions
Acute myocardial infarction was defined as resting chest pain lasting
30 minutes accompanied by ST-segment elevation evolving into
pathological Q waves and was confirmed by the presence of total
creatinine kinase or MB fraction levels of more than twice the upper
normal limit. The absence of any narrowing in coronary diameter
was considered evidence of a normal coronary artery, a narrowing of
70% (50% in the case of the left main coronary artery) was
considered nonsignificant coronary artery stenosis, and a narrowing
of 70% (50% in the case of the left main coronary artery) was
considered significant coronary artery stenosis.
A positive family history was defined as the presence of at least 1
first-degree relative (parent, offspring, or sibling) who had developed
coronary artery disease before the age of 55 years for men and 65
years for women. The subjects were considered to have hypertension
if they had been diagnosed as hypertensive or were taking antihy-
pertensive medication. Their body mass index (BMI) values were
categorized as normal weight (18.5 to 25 kg/m2), preobese (25 to
30 kg/m2), or obese (30 to 35 kg/m2), the last including WHO
classes I, II, and III; underweight subjects were excluded from the
analysis because of their small number. In terms of smoking, the
subjects were classified as current, former, or never smokers on
the basis of self-reports: current smokers were those who reported
smoking regularly during the 3 years preceding the myocardial
infarction; former smokers, those who had smoked regularly for at
least 3 years but not during the year preceding the infarction; and
never smokers, those who had never smoked regularly or had
smoked regularly for 3 years. Never and former smokers were
aggregated in the single category of nonsmokers. The subjects were
considered to have diabetes if they had ever been diagnosed as
having type I or II diabetes by a physician. Hypercholesterolemia
was defined as a fasting total serum cholesterol level of200 mg/dL
(5.2 mmol/L) or the intake of antihypercholesterolemic medications.
Cocaine use was classified as chronic, occasional, or absent at the
time of the index infarction or enrollment. Physical activity was
considered habitual if the subjects engaged in moderately intense
exercise for 30 minutes every day or vigorous exercise for 45
minutes twice a week or 20 minutes 3 times a week. Any other
level of physical activity was considered occasional, and no exercise
was also considered as a separate category. Alcohol consumption
was quantified on the basis of self-reports, with moderate consump-
tion being defined as the intake of 10 to 30 g ethanol/d and high
consumption as 30 g ethanol/d. In the statistical analysis, alcohol
consumption was considered a dichotomous variable (yes/no), with
moderate and high consumers being aggregated in the same
category.
Blood Collection and DNA Analysis
Blood was drawn from the antecubital vein into 3 tubes containing
0.106 M trisodium citrate and separated into plasma and red cells by
centrifugation. DNA was isolated from white blood cells by the
salting-out method. The investigators who performed the determina-
tions were blinded as to whether the sample was from a case patient
or a control. The following polymorphisms of genes encoding
proteins involved in blood coagulation, platelet function, and fibri-
nolysis were analyzed.
Genes Encoding Proteins Involved in
Blood Coagulation
G455A Polymorphism of the -Fibrinogen Gene
The G-to-A substitution located in the -fibrinogen gene promoter
was detected by means of polymerase chain reaction (PCR) and
digestion with the HaeIII restriction enzyme (New England Bio-
Labs). The digestion products were visualized by electrophoretic
separation on 2% agarose gel.4
G1691A Polymorphism of the Factor V Gene
(Factor V Leiden)
The G-to-A substitution was detected by amplifying a region of exon
10 and the adjacent intron of the factor V gene by PCR.5 The 220-bp
fragment was digested with the MnlI restriction enzyme (New
England BioLabs) and visualized on 2% agarose gel.
G20210A Polymorphism of the Prothrombin (Factor II) Gene
For the direct identification of the G-to-A substitution in the
prothrombin gene, genomic DNA was amplified by use of the 5
primer in exon 14 and a mutagenic primer in the 3 untranslated
region.6 The 345-bp fragment was digested with the HindIII restric-
tion enzyme (New England BioLabs) and visualized on 2% agarose
gel.
G10976A Polymorphism of the Factor VII Gene
The G-to-A substitution leading to the replacement of arginine 353
by a glutamine residue was detected by PCR followed by digestion
with the MspI restriction enzyme (New England BioLabs). The
digestion products were visualized on 2% agarose gel.7
Genes Encoding Proteins Involved in
Platelet Function
C807T Polymorphism of the Glycoprotein Ia Gene
The mutagenic primers described by Reiner et al8 were used to
amplify genomic DNA, and the PCR products were digested by the
TaqI restriction enzyme (New England BioLabs). The digestion
products were visualized on 4% agarose gel (2% standard agarose 
2% NuSieve agarose).
C1565T Polymorphism of the Glycoprotein IIIa Gene
The C-to-T substitution was detected by PCR followed by digestion
with the MspI restriction enzyme. The fragments were visualized on
3% agarose gel.9
Genes Encoding Proteins Involved in Fibrinolysis
G185T Polymorphism of the A Subunit Factor XIII Gene
The G-to-T substitution leading to the replacement of a valine by a
leucine residue was detected by PCR followed by digestion with the
BsaHI restriction enzyme (New England BioLabs). The digestion
products were visualized on 3% agarose gel (2% standard agarose 
1% NuSieve agarose).10
4G/5G Polymorphism of the Plasminogen Activator
Inhibitor Type 1 Gene
The single-allele insertion/deletion is situated in the gene promoter
675 bp upstream of the start of transcription and produces a sequence
of either 4 or 5 guanine bases. The genotype was determined by PCR
amplification of genomic DNA using the allele-specific primers
insertion 5G allele, deletion 4G allele, and a common downstream
primer.11 The PCR products were visualized on 2% agarose gel.
Gene Encoding Proteins Involved in
Homocysteine Metabolism
C677T Polymorphism of the Methylenetetrahydrofolate
Reductase Gene
The C-to-T transition leading to the replacement of an alanine by a
valine was detected by PCR. The PCR products were digested by
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HinfI enzyme restriction (New England BioLabs)12 and visualized
on 3% agarose gel (2% standard agarose  1% NuSieve agarose).
Sample Size
Before the study was started, the sample size was calculated on the
basis of the expected relative risk of the mutant allele versus the
wild-type allele, the allelic frequency of the mutant allele, the desired
power, and significance. The allelic frequencies of the 9 poly-
morphisms were obtained from the published data compiled by Tang
and Tracy13 and the results of a previous study carried out in a group
of young Italian patients and controls.14 They ranged from 2% for the
factor V and prothrombin polymorphisms to 46% for the methylene-
tetrahydrofolate reductase (MTHFR) polymorphism, 7 of the 9
polymorphisms having a frequency higher than 10%.13,14 A sample
size of 1210 matched pairs has an 70% power of detecting an OR
of 1.5 with a significance of 5% if the frequency of the mutant allele
is 2%. For frequencies of 10% or higher, the power of detecting an
OR of 1.5 (which was considered to be as high as can be expected in
the context of a multifactorial disease) increases to 90%.
Statistical Analysis
The dependence of disease risk (the response variable) on traditional
and genetic explanatory factors was analyzed with a conditional
logistic regression model; significance was tested by use of the
likelihood ratio test and Wald’s test.15,16 In the regression, the
response variable was defined to take the value of 1 in the cases and
0 in the controls, whereas the set of explanatory variables included
traditional nongenetic and genetic risk factors. In the case of
traditional risk factors having 2 ordered levels (eg, BMI and
physical activity), a test for trend was performed to assess the
departure from linearity. If there was significant evidence of depar-
ture from linearity, the factor was included in the model as a
categorical variable; otherwise, it was included as a quantitative
variable.
The effect of each explanatory factor was expressed as the OR and
95% CI computed from the corresponding estimated regression
coefficient in the model. Adjusted ORs were obtained by use of a
model that included the factor of interest and all of the remaining
factors we wanted to adjust for; unadjusted ORs were obtained by
use of a model that included only the factor of interest. The effect of
each traditional nongenetic risk factor on the risk of myocardial
infarction was estimated by adjustment for all the nongenetic risk
factors with the exception of family history. The OR for family
history was estimated by adjustment for all of the remaining factors.
The 9 genetic factors considered in the analysis represented the
individual’s genotype at the 9 loci mentioned in the preceding
section. Each of these loci was modeled as diallelic, with the wild
type denoted 0 and the mutant allele 1. For each locus, a genetic risk
factor was defined as taking the value x0 when the locus genotype
was 0/0, x1 when it was 0/1, and x2 when it was 1/1. To check
for genotyping errors and/or possible stratifications in the sample,
the deviation from Hardy-Weinberg equilibrium was tested for each
polymorphism in the control group.
The effect of each gene polymorphism was estimated by use of a
multiplicative penetrance model (a genotype of 1/1 representing the
greatest risk, 0/1 an intermediate risk, and 0/0 the lowest risk), which
best agrees with the known association between genotypes at the
various polymorphisms and the corresponding phenotypic variations.
We fitted a model including 1 genetic risk factor at a time (as a
quantitative variable) and all of the nongenetic risk factors found to
be statistically significant in the first step of the analysis.
Results
The case sample consisted of 1061 men and 149 women,
whose mean age at the time of myocardial infarction was
395 years: 11% had normal coronary arteriograms, 10%
nonsignificant stenosis, and 69% significant stenosis.
Table 1 shows the frequency distribution and the unad-
justed and adjusted ORs with their 95% CIs for the
traditional nongenetic risk factors in the 1210 cases and
controls. BMI and physical activity were analyzed as
quantitative variables, because the test for trend did not
reveal any evidence of a statistically significant departure
from linearity. Smoking and, to a lesser extent, diabetes
and hypertension were the traditional nongenetic risk
factors with the strongest effect; the effects of BMI and
hypercholesterolemia were significant, but their magni-
tudes were smaller. The significant effect of family history
was less than that of smoking but more than those of BMI
and hypercholesterolemia. Physical exercise had a statis-
tically significant linear protective effect. The effect of
alcohol consumption and cocaine use lost significance
after adjustment for the remaining nongenetic risk factors,
particularly smoking.
Table 2 shows the frequency distribution of the genotypes
and the unadjusted and adjusted ORs with their 95% CIs for
each of the 9 polymorphisms, none of which showed a
TABLE 1. Traditional Risk Factors and Risk of Myocardial












No 12.3 49.2 1.0 1.0
Yes 87.7 50.8 7.4 (5.8–9.6) 7.6 (5.5–10.4)
Diabetes
No 92.2 99.1 1.0 1.0
Type Itype II 7.8 0.9 10.2 (5.1–20.2) 7.4 (2.8–19.1)
Hypertension
No 75.2 94.4 1.0 1.0
Yes 24.8 5.6 6.1 (4.4–8.3) 4.5 (3.0–6.8)
Family history
No 65.8 87.2 1.0 1.0
Yes 34.2 12.8 3.8 (3.0–4.8) 4.0 (2.9–5.6)
BMI
Normal weight 36.1 56.6
Preobese 44.0 36.8 2.1 (1.8–2.4) 1.6 (1.3–1.9)
Obese class I–III 19.9 6.6
Hypercholesterolemia
No 36.9 51.2 1.0 1.0
Yes 63.1 48.8 1.9 (1.6–2.2) 1.4 (1.1–1.8)
Alcohol
No 40.0 45.0 1.0 1.0
Yes 60.0 55.0 1.2 (1.0–1.5) 1.1 (0.9–1.5)
Cocaine use
No 98.0 99.3 1.0 1.0
Yes 2.0 0.7 3.1 (1.4–6.9) 2.3 (0.8–6.7)
Physical exercise
No 51.2 37.1
Occasional 23.7 28.5 0.7 (0.6–0.8) 0.7 (0.6–0.9)
Routine 25.1 34.4
Values are percentages.
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significant association, whether it was adjusted or unadjusted
for the nongenetic risk factors.
Discussion
The importance of hemostasis in the pathogenesis of acute
myocardial infarction has been firmly established by patho-
logical and angiographic findings of coronary thrombosis and
by the knowledge that the plasma levels of the proteins
involved in the hemostatic mechanism (such as fibrinogen,
factor VII, tissue plasminogen activator antigen, and its
principal inhibitor) are associated with susceptibility to or
protection against myocardial infarction, especially in
younger patients.17,18 In addition, a family history of myocar-
dial infarction is a well-established risk factor in the
young,19–21 and this may mean that a genetic component is
particularly important in these patients.
This matched case-control study was designed to assess
whether or not 9 previously evaluated polymorphisms of
genes encoding proteins involved in hemostasis had an effect
on the risk of myocardial infarction in a series of patients who
TABLE 2. Gene Polymorphisms and the Risk of Developing Myocardial













0/1 35.1 32.9 1.0 (0.9–1.1) 1.0 (0.8–1.2)
1/1 4.4 5.6
G1691A factor V gene




0/1 3.3 3.1 1.0 (0.6–1.5) 1.0 (0.5–1.9)
1/1 0.1
G10976A factor VII gene
0/0 71.8 71.3
0/1 26.5 26.9 1.0 (0.8–1.1) 1.0 (0.8–1.3)
1/1 1.7 1.8
C807T platelet glycoprotein Ia gene
0/0 41.3 39.9
0/1 44.3 46.0 1.0 (0.8–1.1) 1.1 (0.9–1.3)
1/1 14.4 14.1
C1565T platelet glycoprotein IIIa gene
0/0 73.0 71.5












0/1 45.2 51.2 1.0 (0.9–1.1) 0.9 (0.8–1.1)
1/1 24.1 20.8
0/0 indicates genotype associated with the presence of 2 wild-type alleles; 0/1, the presence of
1 wild-type and 1 mutant allele; 1/1, the presence of 2 mutant alleles.
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developed the disease before the age of 45 years. The main
feature of this study is the type of patients, who were selected
on the basis of the likelihood of experiencing a myocardial
infarction because of a prothrombotic state rather than ath-
erosclerosis. Moreover, the sample size (1210 cases and 1210
matched controls) is much larger than that of most previously
reported studies on hemostasis-related genes.1,2 The cases and
controls were matched by place of origin, as well as by age
and sex, to avoid any possible sample stratification that might
lead to spurious associations. None of the 9 polymorphisms
deviated from Hardy-Weinberg equilibrium, thus providing
no evidence of population stratification and/or genotyping
error. The allelic frequencies of all of the polymorphisms
were very similar to those reported in the literature,13 except
for the MTHFR gene polymorphism, the frequency of which
is relatively higher in the Italian population.14,22
The traditional nongenetic risk factors for cardiovascular
disease, such as smoking and family history, were highly
associated with premature myocardial infarction, in general
agreement with previous reports of smaller series.3 Despite
our appropriate study design and adequate sample size, none
of the polymorphisms investigated were associated with the
occurrence of myocardial infarction, unlike the findings of
several other reports reviewed by Lane and Grant1 and Reiner
et al.2 As a typical example of discrepant results, a pilot study
of 200 Italian patients with premature myocardial infarction
(different from those involved in this study) found that the
C1565T polymorphism of the platelet glycoprotein IIIa gene
was associated with an increased risk of myocardial infarc-
tion, particularly in smokers.14
One limitation of this study is that only patients who had
survived a myocardial infarction were enrolled. It cannot be
excluded that prothrombotic mutations may be associated
with more severe myocardial infarctions and a larger number
of early deaths; thus, their effect on the risk of myocardial
infarction may be underestimated. Only prospective studies
on large series of young healthy individuals followed up until
they reach the end points of myocardial infarction and cardiac
death could overcome the limitation of this study.
In conclusion, on the basis of this analysis of the most
frequently investigated polymorphisms of genes encoding
hemostasis factors, it seems that the role of an inherited
predisposition to thrombosis in a complex, polygenic, and
multifactorial disease such as myocardial infarction is weak
in itself and weaker than that of traditional nongenetic risk
factors. From a clinical perspective, there is apparently no
evidence supporting the usefulness of screening individuals at
risk using the studied gene polymorphisms. However, other
recently evaluated gene polymorphisms not considered in this
study may be important contributors in combination with
traditional risk factors or acquired prothrombotic stimuli.23,24
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